Department of Obstetrics and Gynecology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer Med. 2020 Nov;9(21):8122-8132. doi: 10.1002/cam4.3322. Epub 2020 Sep 12.
Ovarian cancer is one of the most common gynecological cancers with high morbidity and mortality, which seriously endangers women's health and quality of life. Long noncoding RNAs (lncRNAs) can regulate the progression of cancers, including ovarian cancer. LINC00857 (long intergenic non-protein coding RNA 857) has been discovered to be a crucial factor in the regulation of cancer development. Nevertheless, the specific functions and mechanisms of LINC00857 in ovarian cancer remain unclear. The Hippo signaling pathway can involve in cancer progression. In our research, we aimed to investigate the correlation of LINC00857 and Hippo pathway. Quantitative real-time polymerase chain reaction assay was utilized to test the expression of LINC00857 in ovarian cancer tissues and cells. Functional experiments revealed that LINC00857 silencing led to the inhibition on cell proliferation, migration, invasion, and glycolysis but accelerated cell apoptosis in ovarian cancer. Mechanism experiments, including RNA immunoprecipitation, RNA pull-down, and luciferase reporter experiments demonstrated that LINC00857 could regulate YAP1 (Yes1 associated transcriptional regulator) by competitively binding to miR-486-5p in ovarian cancer. In a word, this study unveiled that LINC00857 regulates YAP1 by competitively binding to miR-486-5p and accelerates ovarian cancer progression.
卵巢癌是最常见的妇科癌症之一，具有高发病率和死亡率，严重危害妇女的健康和生活质量。长链非编码 RNA（lncRNA）可以调节癌症的进展，包括卵巢癌。LINC00857（长基因间非蛋白编码 RNA 857）已被发现是调节癌症发展的关键因素。然而，LINC00857 在卵巢癌中的具体功能和机制尚不清楚。Hippo 信号通路可以参与癌症的进展。在我们的研究中，我们旨在研究 LINC00857 和 Hippo 通路之间的相关性。实时定量聚合酶链反应检测用于检测卵巢癌组织和细胞中 LINC00857 的表达。功能实验表明，LINC00857 沉默导致卵巢癌细胞增殖、迁移、侵袭和糖酵解能力受到抑制，而促进细胞凋亡。机制实验，包括 RNA 免疫沉淀、RNA 下拉和荧光素酶报告基因实验表明，LINC00857 可以通过与 miR-486-5p 竞争结合来调节 YAP1（Yes1 相关转录调节剂）在卵巢癌中。总之，本研究揭示了 LINC00857 通过与 miR-486-5p 竞争结合来调节 YAP1，并加速卵巢癌的进展。
